BEYOND AIR INC. DL-,0001 (48L.BE)
Chart Events
Performance Outlook
| Previous Close | 5.90 |
| Open | 5.93 |
| Bid | 5.91 x N/A |
| Ask | 6.14 x N/A |
| Day's Range | 5.91 - 6.21 |
| 52 Week Range | 4.63 - 11.37 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Jun 26, 2023 - Jun 30, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Beyond Air® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer
Dr. Myers brings extensive executive experience leading the development of clinical programs through US and global regulatory approvalGARDEN CITY, N.Y., March 23, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through i
- GlobeNewswire
Beyond Cancer™ to Present Two Posters for Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2023 AACR Annual Meeting
Proffered abstracts accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting were released publicly today at 4:30 PM EDTGARDEN CITY, N.Y. and HAMILTON, Bermuda, March 14, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced that Beyond Cancer, Ltd. will present two posters at the upcoming American
- GlobeNewswire
Beyond Air® Announces Participation at Two Upcoming Investor Conferences in March 2023
GARDEN CITY, N.Y., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that St
